CytomX Therapeutics (CTMX) Net Margin (2016 - 2025)
CytomX Therapeutics (CTMX) has disclosed Net Margin for 12 consecutive years, with 238.62% as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Net Margin fell 25578.0% year-over-year to 238.62%, compared with a TTM value of 24.66% through Sep 2025, up 1373.0%, and an annual FY2024 reading of 23.08%, up 2364.0% over the prior year.
- Net Margin was 238.62% for Q3 2025 at CytomX Therapeutics, down from 0.83% in the prior quarter.
- Across five years, Net Margin topped out at 49.55% in Q4 2024 and bottomed at 927.7% in Q4 2022.
- Average Net Margin over 5 years is 146.97%, with a median of 26.01% recorded in 2024.
- The sharpest move saw Net Margin crashed -61488bps in 2022, then skyrocketed 93084bps in 2023.
- Year by year, Net Margin stood at 312.82% in 2021, then crashed by -197bps to 927.7% in 2022, then soared by 100bps to 3.15% in 2023, then soared by 1475bps to 49.55% in 2024, then crashed by -582bps to 238.62% in 2025.
- Business Quant data shows Net Margin for CTMX at 238.62% in Q3 2025, 0.83% in Q2 2025, and 46.2% in Q1 2025.